The REACH SVR Registry is a prospective clinical study designed to evaluate the safety, adherence, and efficacy of prescribed, patient-administered therapy with Infergen^® (Interferon alfacon-1) and other prescribed therapies in patients chronically infected with HCV.

To learn more about the REACH SVR Registry, visit the following website: www.clinicaltrials.gov